

## Product datasheet for **TL312991V**

### FGF17 Human shRNA Lentiviral Particle (Locus ID 8822)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	FGF17 Human shRNA Lentiviral Particle (Locus ID 8822)
Locus ID:	8822
Synonyms:	FGF-13; FGF-17; HH20
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	FGF17 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_001304478</a> , <a href="#">NM_003867</a> , <a href="#">NM_003867.2</a> , <a href="#">NM_003867.3</a> , <a href="#">BC105131</a> , <a href="#">BC105131.1</a> , <a href="#">BC069475</a> , <a href="#">BC113489</a> , <a href="#">BC143789</a> , <a href="#">BM666883</a> , <a href="#">NM_003867.4</a>
UniProt ID:	<a href="#">O60258</a>
Summary:	This gene encodes a member of the fibroblast growth factor (FGF) family. Member of the FGF family possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. This protein is expressed during embryogenesis and in the adult cerebellum and cortex and may be essential for vascular growth and normal brain development. Mutations in this gene are the cause of hypogonadotropic hypogonadism 20 with or without anosmia. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jan 2015]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).